ATE419368T1 - System zum transfer und zur expression von heterologen genen ins knochenmark in vivo - Google Patents

System zum transfer und zur expression von heterologen genen ins knochenmark in vivo

Info

Publication number
ATE419368T1
ATE419368T1 AT98906462T AT98906462T ATE419368T1 AT E419368 T1 ATE419368 T1 AT E419368T1 AT 98906462 T AT98906462 T AT 98906462T AT 98906462 T AT98906462 T AT 98906462T AT E419368 T1 ATE419368 T1 AT E419368T1
Authority
AT
Austria
Prior art keywords
infectious
bone marrow
disclosed
virus
bone
Prior art date
Application number
AT98906462T
Other languages
English (en)
Inventor
Robert Johnston
Dennis Simpson
William B Klimstra
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Application granted granted Critical
Publication of ATE419368T1 publication Critical patent/ATE419368T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98906462T 1997-02-19 1998-02-18 System zum transfer und zur expression von heterologen genen ins knochenmark in vivo ATE419368T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/801,263 US5811407A (en) 1997-02-19 1997-02-19 System for the in vivo delivery and expression of heterologous genes in the bone marrow

Publications (1)

Publication Number Publication Date
ATE419368T1 true ATE419368T1 (de) 2009-01-15

Family

ID=25180622

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98906462T ATE419368T1 (de) 1997-02-19 1998-02-18 System zum transfer und zur expression von heterologen genen ins knochenmark in vivo

Country Status (8)

Country Link
US (3) US5811407A (de)
EP (1) EP0989863B1 (de)
JP (1) JP2001515348A (de)
AT (1) ATE419368T1 (de)
AU (1) AU749903B2 (de)
CA (1) CA2281858C (de)
DE (1) DE69840403D1 (de)
WO (1) WO1998036779A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU757549B2 (en) 1998-03-27 2003-02-27 Cytos Biotechnology Ag Inducible alphaviral gene expression system
AU767551B2 (en) * 1998-06-29 2003-11-13 U.S. Medical Research Institute Of Infectious Diseases Marburg virus vaccines
US6451579B1 (en) 1998-07-29 2002-09-17 Invitrogen Corporation Regulated expression of recombinant proteins using RNA viruses
JP2002523053A (ja) * 1998-07-30 2002-07-30 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 標的化されたアルファウイルスおよびアルファウイルスベクター
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
ATE463578T1 (de) * 1999-04-14 2010-04-15 Novartis Vaccines & Diagnostic Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren- systeme
US8647864B2 (en) * 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
WO2001042442A2 (en) 1999-12-10 2001-06-14 Cytos Biotechnology Ag Activation of endogenous genes by genomic introduction of a replicon
JP5502253B2 (ja) 2000-02-23 2014-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規化合物
AU2001249380A1 (en) * 2000-03-22 2001-11-07 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
DK1285080T3 (da) 2000-05-31 2008-12-01 Novartis Vaccines & Diagnostic Fremgangsmåde til oprensning af alphavirusreplikonpartikler
AU2001273149A1 (en) 2000-06-28 2002-01-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
AU2001290642A1 (en) * 2000-09-07 2002-03-22 University Of North Carolina At Chapel Hill Vectors derived from south african arbovirus no. 86
EP1515982A4 (de) 2001-05-09 2005-10-26 Corixa Corp Zusammensetzungen und verfahren zur therapie und diagnose von prostatakrebs
US20030077251A1 (en) * 2001-05-23 2003-04-24 Nicolas Escriou Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins
JP4790984B2 (ja) * 2001-09-06 2011-10-12 アルファヴァックス，インコーポレイテッド アルファウイルスレプリコンベクター系
CA2860702C (en) 2001-12-17 2019-02-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
DK2290054T3 (en) * 2002-12-13 2017-07-03 Alphavax Inc Alpha virus particles and processes for their preparation
ES2618309T3 (es) 2002-12-13 2017-06-21 Alphavax, Inc. Partículas de replicón de alfavirus multi-antigénico y métodos
SI1589934T1 (sl) 2003-01-06 2016-02-29 Corixa Corporation Corporation Service Company Določene aminoalkil glukozaminid fosfat spojine in njih uporaba
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
KR101454842B1 (ko) * 2003-03-20 2014-11-04 알파벡스, 인크. 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
US7419674B2 (en) * 2003-07-11 2008-09-02 Alpha Vax, Inc. Alpha virus-based cytomegalovirus vaccines
US8574590B2 (en) * 2003-07-30 2013-11-05 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
CA2567254C (en) 2004-05-18 2012-03-13 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
JP4896021B2 (ja) * 2004-05-21 2012-03-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 呼吸器系病原体ワクチンのためのアルファウイルスベクター
WO2006085983A2 (en) * 2004-07-09 2006-08-17 University Of North Carolina At Chapel Hill Viral adjuvants
BRPI0515520A (pt) 2004-09-22 2008-07-29 Glaxosmithkline Biolog Sa composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
WO2007046839A2 (en) * 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
EP2441846A3 (de) 2006-01-09 2012-07-25 The Regents Of the University of California Immunstimulierende Kombinationen aus TNFRSF, TLR, NLR, RHR, purinergischem Rezeptor, und Zytokin-Rezeptor-Antagonisten für Impfstoffe und die Tumorimmuntherapie
EP2061508B1 (de) * 2006-09-12 2014-10-15 Alphavax, Inc. An protein-antigene angepasste alphavirus replikons als immunologisches adjuvant
DK2099485T3 (en) * 2006-11-03 2018-05-22 Alphavax Inc Alphavirus and alphavirus replica particle formulations and associated methods
AU2008266807B2 (en) * 2007-06-21 2012-08-16 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
US8680258B2 (en) 2008-12-01 2014-03-25 Alphavax, Inc. Use of microRNAs to control virus helper nucleic acids
AU2010234362B2 (en) 2009-04-08 2015-11-26 Alphavax, Inc. Alphavirus replicon particles expressing TRP2
WO2011041478A1 (en) 2009-10-02 2011-04-07 Baxter International Inc. Hematopoietic stem cells for use in the treatment of a kidney injury
US9422529B2 (en) 2010-12-22 2016-08-23 The Board Of Regents Of The University Of Texas System Alphavirus compositions and methods of use
WO2012088473A1 (en) 2010-12-22 2012-06-28 The Board Of Regents Of The University Of Texas System Alphavirus compositions and methods of use
EP2723365A1 (de) 2011-06-21 2014-04-30 Oncofactor Corporation Zusammensetzungen und verfahren zur behandlung und diagnose von krebs
US20130216495A1 (en) 2012-02-21 2013-08-22 Baxter Healthcare Sa Pharmaceutical composition comprising cd34+ cells
SG11201407595UA (en) 2012-05-21 2014-12-30 Univerisity Of California Generation of human ips cells by a synthetic self- replicative rna
JP2018511655A (ja) 2015-03-20 2018-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物
EP3310368A4 (de) * 2015-06-19 2018-12-19 Seracare Life Sciences Inc. Sindbis-kontrollvirus
EP3403660A4 (de) * 2016-01-14 2019-08-21 Industry - University Cooperation Foundation Hanyang University Verfahren mit verwendung der expression von lin28 zur verwendung von stammzellen mit ausgezeichneter erneuerbarkeit und differenzierungspotenzial
GB201603374D0 (en) 2016-02-26 2016-04-13 Ucl Business Plc Packaging cell
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
US10960071B2 (en) 2017-08-07 2021-03-30 The Regents Of The University Of California Platform for generating safe cell therapeutics
CA3072329A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California Platform for generating safe cell therapeutics

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US6156304A (en) 1990-12-20 2000-12-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for studying and treating a connective tissue of a mammalian host
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0716148B1 (de) * 1993-09-15 2004-01-02 Chiron Corporation Rekombinanter Alphavirus Vektor
SE9401091D0 (sv) * 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5639650A (en) 1995-05-23 1997-06-17 The University Of North Carolina At Chapel Hill cDNA clone for South African Arbovirus No. 86
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
WO1997038087A2 (en) * 1996-04-05 1997-10-16 Chiron Corporation Alphaviral vector with reduced inhibition of cellular macromolecular synthesis

Also Published As

Publication number Publication date
US6583121B1 (en) 2003-06-24
US6008035A (en) 1999-12-28
US5811407A (en) 1998-09-22
EP0989863B1 (de) 2008-12-31
EP0989863A2 (de) 2000-04-05
WO1998036779A3 (en) 1999-04-22
CA2281858A1 (en) 1998-08-27
AU6168298A (en) 1998-09-09
DE69840403D1 (de) 2009-02-12
AU749903B2 (en) 2002-07-04
WO1998036779A2 (en) 1998-08-27
JP2001515348A (ja) 2001-09-18
CA2281858C (en) 2011-01-25

Similar Documents

Publication Publication Date Title
ATE419368T1 (de) System zum transfer und zur expression von heterologen genen ins knochenmark in vivo
CN105821039B (zh) 联合免疫基因抑制HBV复制的特异性sgRNA、表达载体及其应用
Luytjes et al. Sequence of mouse hepatitis virus A59 mRNA 2: indications for RNA recombination between coronaviruses and influenza C virus
CN103930551B (zh) 猴腺病毒和杂合腺病毒载体
RU2233333C2 (ru) Вирусные векторы и их применение в генной терапии
Lipskaya et al. Frequent isolation of intertypic poliovirus recombinants with serotype 2 specificity from vaccine‐associated polio cases
RU95122419A (ru) Вирусные векторы и их применение в генной терапии
YU37502A (sh) Infektivni klonovi
EP1736539A1 (de) Abgeschwächte SARS-CoV Impfstoffe
HU229101B1 (en) Dna transfection system for the generation of infectious influenza virus
CA2447450A1 (en) Corona-virus-like particles comprising functionally deleted genomes
DE69737886D1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
ATE205537T1 (de) Verwendung von plasmiden zur herstellung eines impfstoffs bei mensch und tier
DE69534600D1 (de) Nukleotid- und aminosäuresequenzen der gene des hüllproteins 1 und des kernproteins von hepatitis c virus
Graff et al. Mutational events in consecutive passages of hepatitis A virus strain GBM during cell culture adaptation
JP2005519591A (ja) 毛包成長
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
BR9815285A (pt) Vetores alfavìrus para vacina de paramixovìrus
HU228469B1 (en) Attenuated pestiviruses, their use, and nuclein acids for their production
RU2002100209A (ru) Gm-csf лошади
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
US20060171962A1 (en) SARS vaccine
PT1009768E (pt) Persefina e factores de crescimento relacionados
HUP0200320A2 (hu) Macskaeredetű CD28-at, CD80-at, CD86-ot vagy CTL4-A-t expresszáló rekombináns vírusok és alkalmazásuk
WO2022006306A2 (en) Compositions for genome editing and methods of use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties